Understanding the origins of insulin-producing beta cells of the pancreas could lead to new
treatments for diabetes. Collombat et al.(2009) now show that in response to injury, a …

New insulin-producing β cells are produced throughout adult life and could potentially be
exploited in regenerative therapies for diabetes. Although pancreatic progenitor cell …

Replacing missing insulin-producing β cells to treat diabetes is a major challenge for
regenerative medicine. A better understanding of β-cell embryogenesis and regeneration in …

In both type 1 and type 2 diabetes, insufficient numbers of insulin-producing β cells are a
major cause of defective control of blood glucose and its complications. Accordingly …

It is well-established that insulin-producing pancreatic beta cells are central in diabetes. In
type 1 diabetes, beta cells are destroyed by an autoimmune mechanism, whereas in type 2 …

Beta-cell deficit is the major pathological feature in type 1 and type 2 diabetes patients, and
plays a key role in disease progression. In principle, beta-cell regeneration can occur by …

Both type 1 and type 2 diabetes patients would greatly benefit from transplantation of insulin‐
producing pancreatic beta cells; however, a severe shortage of transplantable beta cells is a …

It has been suggested that new beta cells can arise from specific populations of adult
pancreatic progenitors or facultative stem cells. However, their existence remains …

The natural source for new pancreatic beta cells is an important issue both for
understanding the pathogenesis of diabetes, and for possibly curing diabetes by increasing …

Cell therapy means treating diseases with the body's own cells. One of the cell types most in
demand for therapeutic purposes is the pancreatic β‐cell. This is because diabetes is one of …